Canada’s Michael Smith Genome Sciences Centre (GSC) introduced clinical whole genome sequencing for hereditary cancer testing in 2025 in collaboration with the Hereditary Cancer Program at BC Cancer and the Cancer Genetics and Genomics Laboratory with the Provincial Laboratory Medicine Services. This marked a major milestone for precision medicine in British Columbia and becoming the second Canadian province to adopt this latest technology.
This initiative provides a new foundation for cancer prevention, diagnosis and treatment. By sequencing a patient’s entire genome from the outset, researchers and clinicians gain a more complete picture of genetic factors that may contribute to cancer risk.
“This milestone reflects the strength of our partnership and our shared commitment to advancing precision medicine in BC. The introduction of whole-genome sequencing enhances our ability to support healthier outcomes for patients and families across the province by improving how cancer can be diagnosed and treated.”
– Dr. Federica Di Palma, Interim Senior Executive Director, Canada’s Michael Smith Genome Sciences Centre, and Dr. Alexander Wyatt, UBC President’s Excellence Chair in Precision Oncology and BC Cancer Senior Scientist
Whole genome sequencing strengthens the province’s ability to advance research by generating rich, comprehensive genomic data, and to improve care by supporting the potential for more accurate risk assessments and personalized treatment plans.
The introduction of whole genome sequencing supports BC’s 10-year Cancer Action Plan priority to strengthen and expand best practice screening programs by providing timely and cost-efficient access to hereditary cancer screening services.
BC Cancer Foundation provided the philanthropic support that established the GSC in 1999 and has continued to fund genomic programs and technological and research advancements over the years. Their ongoing support has been critical in bringing whole genome sequencing into clinical practice and ensuring B.C. remains at the forefront of precision oncology and cancer research.
This advancement positions the GSC as a national and international leader in precision medicine and, unlocks new possibilities to drive translational research and discovery in cancer.
